Clinical trial Recruiting at 2 sites Interventional Ages 18 and up

Evaluating a new treatment approach for borderline personality disorder

Official title: A Pragmatic Non-randomized Controlled Study Evaluating the Efficacy of a Dimensional Adaptation of Good Psychiatric Management (GPM-extended) Compared to a Classic Outpatient Good Psychiatric Management Treatment for Patient Fulfilling Criteria for Borderline Personality Disorder

Run by AddiPsy · NCT06913738 · Data updated 2026-11-12

This study is testing a new personalized treatment for borderline personality disorder to see if it works better than the standard approach.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment154 (estimated)
SponsorAddiPsy
Academic / other
Locations2 sites (Bayonne and 1 other locations)
StatusRecruiting
StartedJune 19, 2024
Main results expectedDecember 2029
Study endsDecember 2029
Registry record updatedApril 9, 2025
Trial IDNCT06913738 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 and older diagnosed with borderline personality disorder.

Probably not a fit

Patients with comorbid psychotic disorders, severe antisocial traits, or those unable to cooperate with the study requirements may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the effectiveness of a dimensional adaptation of Good Psychiatric Management (GPM-extended) compared to classic GPM in treating adults with borderline personality disorder (BPD). The GPM-extended model incorporates elements from adaptations for narcissistic and obsessive-compulsive personality disorders, providing a personalized treatment approach. Researchers will evaluate changes in BPD symptom severity and related clinical outcomes over one year of treatment by comparing two patient groups: those receiving GPM-extended and those receiving classic GPM.

Why it matters

Potential benefit: If successful, this approach could lead to improved treatment outcomes for patients with borderline personality disorder.

How similar studies have gone: While the dimensional approach to personality disorders is gaining attention, this specific adaptation of GPM has not been widely tested in clinical settings.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults (≥18 years old)
* Diagnosis of borderline personality disorder according to the SCID-II (≥5 out of 9 criteria)
* Provision of written informed consent
* Affiliated with or beneficiary of the French national health insurance system

Exclusion criteria

* Age under 18 years
* Presence of a comorbid psychotic disorder, intellectual disability, severe antisocial traits, major substance use disorder incompatible with intensive therapy without abstinence, anorexia nervosa with somatic risk, or bipolar disorder in acute manic phase
* Individuals under legal protection (e.g., guardianship or legal safeguard)
* Individuals unable to cooperate or complete self- or clinician-administered questionnaires
* Individuals not affiliated with or not beneficiaries of the French national health insurance system

Where it's running

  • Clinique Caradoc
    Bayonne, France
    Recruiting
  • Addipsy
    Lyon, France
    Recruiting

Study contacts

  • Principal investigator: Martin Blay, M.D., M.Sc — AddiPsy
  • Study coordinator: Martin Blay, M.D., M.Sc
  • Email: m.blay@addipsy.com
  • Phone: +33472943403

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.